This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine

This study has been completed.
Information provided by (Responsible Party):
PATH Identifier:
First received: January 7, 2013
Last updated: December 22, 2016
Last verified: October 2013
This study will evaluate 3 doses of a new vaccine for rotavirus infection in healthy adult volunteers to determine if it is safe and if the immune systems of healthy adults respond to this vaccine.

Condition Intervention Phase
Rotavirus Infection Biological: P2-VP8 subunit rotavirus vaccine Other: placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 1 Double Blinded, Randomized, Placebo-controlled Dose Escalation Study to Examine the Safety, Reactogenicity, Tolerability and Immunogenicity of the P2-VP8 Subunit Rotavirus Vaccine in Healthy Adult Volunteers

Resource links provided by NLM:

Further study details as provided by PATH:

Primary Outcome Measures:
  • safety [ Time Frame: day 84 ]
    occurrence of Serious Adverse Events

Secondary Outcome Measures:
  • immunogenicity [ Time Frame: 4 weeks post 3rd immunization ]
    proportion of patients with anti-P2-VP8 IgA and IgG seroresponse

Enrollment: 48
Study Start Date: December 2012
Study Completion Date: September 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: P2-VP8 subunit rotavirus vaccine
3 doses of P2-VP8 subunit rotavirus vaccine 4 weeks apart
Biological: P2-VP8 subunit rotavirus vaccine
3 doses of P2-VP8 subunit rotavirus vaccine given 4 weeks apart
Placebo Comparator: Placebo group
12 subjects receiving 3 intramuscular injections of placebo 4 weeks apart
Other: placebo
3 doses of IM placebo given 4 weeks apart


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • A qualified volunteer must be:

    1. Healthy male or female between 18 and 45 (inclusive) years of age at time of enrollment.
    2. Willing and able to give informed consent - must pass test of comprehension with > 70% correct within two attempts.
    3. If female and of childbearing potential, be not breastfeeding and not pregnant (based on a negative serum pregnancy test at screening and a negative urine pregnancy test during the 24 hours prior to first injection), planning to avoid pregnancy for at least 4 weeks after the last injection, and willing to use an adequate method of contraception consistently and have repeated pregnancy tests prior to second and third injections.
    4. Willing to comply with study restrictions and study schedule (as evidenced by a signed informed consent form [ICF] and assessment by the PI or designee).
    5. Able and willing to be contacted by telephone or text, and willing for study staff to record telephone voice or text messages as needed.

      Exclusion Criteria:

  • A qualified volunteer must not:

    1. Have received an investigational product during the 30 days prior to randomization.
    2. Intend to receive another investigational product during this study.
    3. Have any contraindication to parenteral injections (e.g., history of bleeding disorder).
    4. Have previously received a marketed or investigational rotavirus vaccine.
    5. Have a history of severe local or systemic reaction to any vaccine.
    6. Have a history of recurrent urticaria of unknown cause.
    7. Have a history of any allergic or infusion reaction that was severe (e.g., anaphylactic or anaphylactoid), generalized (e.g., drug rash, urticaria, angioedema) or that, in the opinion of the PI, significantly increases risk of severe local or systemic reaction to an investigative vaccine.
    8. Have a history of reaction to any vaccine that, in the opinion of the PI, significantly increases risk of severe reaction to an investigative vaccine.
    9. Have received any vaccine within 4 weeks prior to randomization or planned vaccination through Day 84.
    10. Have received any blood product or any immunomodulating agent (e.g., immunoglobulin, interferon, growth factor) within 12 weeks prior to randomization.
    11. Have received immunosuppressive medications (e.g., prolonged use of systemic corticosteroid or cytotoxic agent) within the 24 weeks prior to randomization. Eligible if a short course (≤10 days) of systemic corticosteroid concluded more than 2 weeks prior to randomization, use of inhaled corticosteroid for asthma, and use of topical corticosteroid for a skin condition.
    12. Have a history of any clinically significant (in the opinion of the PI) immunosuppressive or autoimmune condition.
    13. Anticipate need for administration of any blood product, immunosuppressive (e.g., systemic corticosteroid), or immunomodulatory treatment during the study.
    14. Have a history of malignancy, excluding basal cell carcinoma.
    15. Have Diabetes Mellitus Type I or II.
    16. Have a positive test for HIV-1, HBsAg or anti-HepC.
    17. Have significant abnormalities in screening laboratory test results or clinical assessment as determined by the PI or by the PI in consultation with the Sponsor's medical officer.*
    18. Have abnormal vital signs deemed clinically relevant by the PI.*
    19. Evidence of current or recent (within past 12 months) excessive alcohol consumption or drug dependence.
    20. Have any condition of hand, arm or related lymph nodes that may confound post-dose assessments.
    21. Have any condition (medical, psychiatric or behavioral) that, in the opinion of the PI, would increase the volunteer's health risks in study participation or would increase the risk of not achieving the study's objectives
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01764256

United States, Maryland
Center for Immunization Research
Baltimore, Maryland, United States, 21205
Sponsors and Collaborators
Principal Investigator: Clayton Harro, MD Johns Hopkins Bloomberg School of Hygiene and Public Health
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: PATH Identifier: NCT01764256     History of Changes
Other Study ID Numbers: VAC 009
Study First Received: January 7, 2013
Last Updated: December 22, 2016

Keywords provided by PATH:

Additional relevant MeSH terms:
Rotavirus Infections
Reoviridae Infections
RNA Virus Infections
Virus Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on July 19, 2017